Compound for inhibiting expression of PKK mRNA and protein, composition thereof, and use thereof

By designing compounds with specific oligonucleotides complementary to the KLKB1 genome, and utilizing RNA interference and steric hindrance mechanisms, the problem of poor inhibition of PKK mRNA and protein expression in existing technologies has been solved, achieving effective inhibition of PKK and demonstrating potential application in the treatment of inflammatory and thromboembolic symptoms.

WO2026238082A1PCT designated stage Publication Date: 2026-11-19CHOLESGEN (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/097107
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing antisense oligonucleotides have failed to effectively inhibit PKK mRNA and protein expression in terms of in vitro and in vivo activity, and the target inhibition effect is not ideal.

Method used

A compound was designed that utilizes an RNA interference mechanism and an RNase H-mediated mRNA degradation mechanism. It employs a specific oligonucleotide complementary to the KLKB1 genomic sequence and combines steric hindrance to inhibit PKK mRNA maturation and translation. The compound contains modified nucleotides and nucleoside bonds and may be conjugated to a target ligand for delivery to cells or tissues.

Benefits of technology

It achieves effective inhibition of PKK mRNA and protein expression, with the potential to treat and prevent inflammatory and thromboembolic symptoms, and can be applied to pharmaceutically acceptable vector delivery systems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026097107-FTAPPB-I100001
    Figure PCTCN2026097107-FTAPPB-I100001
  • Figure PCTCN2026097107-FTAPPB-I100002
    Figure PCTCN2026097107-FTAPPB-I100002
  • Figure PCTCN2026097107-FTAPPB-I100003
    Figure PCTCN2026097107-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention relates to a compound or a salt thereof for inhibiting the expression of prekallikrein (PKK), a composition comprising same, and use thereof. The compound or the salt thereof of the present invention achieves the purpose of disease prevention and treatment by means of inhibiting the expression of PKK.
Need to check novelty before this filing date? Find Prior Art

Description

A compound that inhibits PKK mRNA and protein expression, its composition and application Technical Field

[0001] This invention relates to compounds that inhibit the expression of prekallikrein (PKK), as well as their compositions and uses. Background Technology

[0002] Plasma prekallikrein (PKK) is a precursor of plasma kallikrein (PK) encoded by the KLKB1 gene. PKK is a surface-dependent glycoprotein involved in blood coagulation, fibrinolysis, kinin production, and inflammation. PKK is converted from factor XIIa to PK by cleaving the internal Arg-Ile peptide bond. PK releases kinin from kininogen and is also converted from plasminogen to plasmin. PK is a member of the kallikrein pathway, which consists of several proteins that play roles in inflammation, blood pressure control, coagulation, and pain.

[0003] Existing technologies disclose several modified antisense oligonucleotides and methods that can reduce PKK mRNA and protein expression. However, existing antisense oligonucleotides have not yet achieved ideal target inhibition effects in terms of in vitro and in vivo activity. Therefore, designing a sequence with higher target inhibitory activity is crucial. Summary of the Invention

[0004] This invention provides compounds, salts thereof, compositions, and methods for reducing the expression of human plasma prokallikrein (PKK) mRNA and protein in animals. The compounds, salts thereof, and compositions of this invention can be used to treat, prevent, or improve inflammatory and thromboembolic symptoms.

[0005] On one hand, this invention provides a compound or its salt for inhibiting PKK mRNA and / or protein expression. Unbound by theoretical constraints, the compound or its salt of this invention can inhibit PKK expression by degrading PKK mRNA or inhibiting the translation of target PKK mRNA in a sequence-specific manner through RNA interference mechanisms via RNase H-mediated mRNA degradation. The compound or its salt of this invention can also inhibit mRNA maturation and translation through steric hindrance effects resulting from binding, thereby inhibiting PKK expression. In some embodiments, the salt is a pharmaceutically acceptable salt.

[0006] In some embodiments, the compounds of the present invention or their salts comprise oligonucleotides complementary to at least a portion of the KLKB1 genomic sequence. In some embodiments, the KLKB1 genomic sequence is selected from the NCBI reference sequence NG_012095.2. In some embodiments, the oligonucleotides are fully or partially complementary to at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides selected from the following regions of the KLKB1 genomic sequence NG_012095.2: 37945-37964, 44885-44904, 52611-52630, 32731-32750, 37946-37965, 51081- 51100, 44406-44425, 37947-37966, 44407-44426, 32864-32883, 30726-30745, 24266-24285, 48199-48218, 24265-24284, 54152-54171, 30725-30744, 29569-29588, 51085-51104, 52612-52631, 29459-29478, 28176-28195, 52009-52028, 52010-52029, 52011-52030, 5201 3-52032, 52014-52033, 52015-52034, 52016-52035, 52059-52078, 52060-52079, 52061-52080, 47588-47607, 47590-47605, 28178-28194, 28179-28193, 52017-52034, 52025-52044, 52027-52046, 53293-53312, 47506-47521, 46254-46269, 34348-34363, 29972-29987, 28 178-28193, 52012-52027, 52017-52032, 54108-54123, 32953-32968, 54105-54120, 52013-52028, 53293-53308, 53293-53307, 53293-53305, 31780-31795, 48197-48212, 30068-30083, 28177-28192, 52062-52077, 48198-48213, 52059-52074, 28176-28191, 54104-54119,52065-52080, 28179-28194, 52019-52034, 52015-52032, 52016-52033, 52019-52032, 52019-52033, 52019-52030, 52015-52033, 52015-52034; wherein the partial complementarity refers to the complementarity of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 nucleotides in the two sequences. In some implementations, the regions are selected from 37945-37964, 44885-44904, 52611-52630, 32731-32750, 53293-53308, 52019-52034, 53293-53308, 53293-53307, 53293-53305, 47588-47607, 47590-47605, 52019-52032, 52019-52030, 52015-52034, and 28177-28192. In some implementations, partial complementarity refers to complementarity of 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in the two sequences. In some implementations, the oligonucleotide is completely complementary to the region of the KLKB1 genomic sequence NG_012095.2.

[0007] In some embodiments, the compounds of the present invention or their salts comprise oligonucleotides, the sequence of which is a 12-23 consecutive nucleotide sequence differing from any of the sequences shown in Table 1, Table 2 or Table 3 by 0, 1, 2, 3, 4 or 5 nucleotides. In some embodiments, the sequence of the oligonucleotide is a 12-23 consecutive nucleotide sequence differing from any of the sequences shown in Table 1, Table 2 or Table 3 by 0, 1 or 2 nucleotides.

[0008] In some embodiments, the oligonucleotide is 12 nucleotides long. In some embodiments, the oligonucleotide is 13 nucleotides long. In some embodiments, the oligonucleotide is 14 nucleotides long. In some embodiments, the oligonucleotide is 15 nucleotides long. In some embodiments, the oligonucleotide is 16 nucleotides long. In some embodiments, the oligonucleotide is 17 nucleotides long. In some embodiments, the oligonucleotide is 18 nucleotides long. In some embodiments, the oligonucleotide is 19 nucleotides long. In some embodiments, the oligonucleotide is 20 nucleotides long. In some embodiments, the oligonucleotide is 21 nucleotides long. In some embodiments, the oligonucleotide is 22 nucleotides long. In some embodiments, the oligonucleotide is 23 nucleotides long.

[0009] In some embodiments, the oligonucleotide sequence is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of the sequences shown in Table 1, Table 2, or Table 3.

[0010] In some embodiments, at least one nucleotide in the oligonucleotide is a modified nucleotide and / or at least one nucleoside internucleotide is a modified nucleoside internucleotide. In some embodiments, the oligonucleotide comprises deoxyribonucleotides and / or ribonucleotides.

[0011] In some embodiments, the modified nucleotide is 5-methylcytosine nucleotide, 2'-O-methoxyethyl (2'-MOE) nucleotide, 2'-O-methyl nucleotide, restricted ethyl (cEt) nucleotide, 3'-fluoro-HNA nucleotide, LNA nucleotide, or a combination thereof. In some embodiments, the modifying group in the modified nucleotide is selected from one or more of 5-methylcytosine (5-mC), 2'-O-methoxyethyl, 2'-O-alkyl, 2'-O-methyl, restricted ethyl (cEt), LNA (locked nucleic acid), 3'-fluoro-HNA (hexitol nucleic acid), 2'-fluorine, 2'-methoxyalkyl, 2'-O-allyl, 2'-C-allyl, BNA (bridged nucleic acid), and THP (tetrahydropyran). Preferably, in some embodiments, the modified nucleotide is a 2'-O-methoxyethyl (2'-MOE) nucleotide, a restricted ethyl (cEt) nucleotide, or a combination thereof.

[0012] In some embodiments, the modified nucleoside internucleotide bond is selected from one or more of phosphate ester (PO), thiophosphate (PS), and mesylate-aminophosphate (MsPA) bonds. In some embodiments, the oligonucleotide contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 phosphate ester bonds. In some embodiments, the oligonucleotide contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mesylate-aminophosphate bonds.

[0013] In some embodiments, the oligonucleotide comprises: i. a 5' wing consisting of 3, 4, 5, or 6 nucleotides linked together; ii. a central spacer consisting of 7, 8, 9, 10, or 11 nucleotides linked together; iii. a 3' wing consisting of 3, 4, 5, or 6 nucleotides linked together; wherein the central spacer is located between the 5' wing and the 3' wing, and at least one nucleotide in the 5' wing and the 3' wing is a modified nucleotide and / or at least one nucleotide-linked internucleotide is a modified nucleotide-linked internucleotide.

[0014] In some embodiments, none of the nucleotides in the central spacer are modified nucleotides. In some embodiments, all nucleotides in the central spacer are deoxyribonucleotides. In some embodiments, the nucleotides in the central spacer are a combination of deoxyribonucleotides and ribonucleotides. In some embodiments, the nucleotides in the central spacer are all connected by phosphate ester bonds. In some embodiments, the nucleotides in the central spacer contain at least one thiophosphate ester bond and / or at least one methanesulfonyl-aminophosphate ester bond.

[0015] In some embodiments, all nucleotides in the 5' and 3' wings are modified nucleotides. In some embodiments, the nucleotides in the 5' wing comprise 2'-O-methoxyethyl (2'-MOE) nucleotides, restricted ethyl (cEt) nucleotides, or combinations thereof. In some embodiments, the nucleotides in the 3' wing comprise 2'-O-methoxyethyl (2'-MOE) nucleotides, restricted ethyl (cEt) nucleotides, or combinations thereof.

[0016] In some implementations, the modifying groups of the modified nucleotides may be the same or different.

[0017] In some embodiments, the modified structure of the oligonucleotide is selected from: 5-10-5 MOE spacers, 4-8-4 MOE spacers, 4-9-4 MOE spacers, 3-8-4 MOE spacers, 4-9-5 MOE spacers, 4-10-4 MOE spacers, 5-9-5 MOE spacers, 3-10-3 cEt spacers, 3-8-3 cEt spacers, 3-9-3 cEt spacers, 3-7-3 cEt spacers, 5-4-1-5-5 MOE spacers. E double spacer, 3-2-10-1-4 MOE / cEt spacer, 4-1-10-5 MOE / cEt spacer, 4-1-10-1-4 MOE / cEt spacer, 2-3-10-1-4 MOE / cEt spacer, 3-1-8-1-3 MOE / cEt spacer, 2-2-8-2-2 MOE / cEt spacer, 3-2-10-5 MOE / cEt spacer, or 2-1-10-2-1 MOE / cEt spacer.

[0018] In some embodiments, the oligonucleotide has any of the oligonucleotide modifications shown in Table 1, Table 2 or Table 3.

[0019] In some embodiments, the oligonucleotide comprises a continuous nucleotide sequence with modifications selected from one or more of SEQ ID NO:1-27, SEQ ID NO:30-48, SEQ ID NO:50-77, SEQ ID NO:80-94, SEQ ID NO:102-112, SEQ ID NO:114-137, and SEQ ID NO:180-200. In some embodiments, the oligonucleotide comprises a continuous nucleotide sequence with modifications selected from one or more of SEQ ID NO:57-63, SEQ ID NO:73-77, SEQ ID NO:80-94, SEQ ID NO:102-110, SEQ ID NO:114-137, and SEQ ID NO:180-200. In some embodiments, the oligonucleotide comprises a continuous nucleotide selected from one or more of the following: SEQ ID NO: 57, 59, 61, 62, 63, 73, 74, 75, 77, 80, 86, 88, 90, 92, 93, 94, 102, 108, 109, 114, 115, 130, 132, 133, 134, 136, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200.

[0020] In some embodiments, the compounds of the present invention or their salts comprise a targeting ligand (targeting group) conjugated to an oligonucleotide. In some embodiments, the targeting ligand is an N-acetyl-galactosamine derivative (GalNAc derivative).

[0021] In some implementations, the targeting ligand is selected from L96, THAGN3, 59GN3, LICA-1, LICA-2, LICA-3, (NAG25), (NAG25)s, (NAG37), or (NAG37)s, with the following structure:

[0022] In some embodiments, the targeting ligand is THAGN3 or 59GN3. Preferably, in some embodiments, the targeting ligand is 59GN3.

[0023] In some embodiments, the targeting ligand is conjugated to the 5' or 3' end of the oligonucleotide. In some embodiments, the targeting ligand is conjugated to the 5' end of the oligonucleotide. In some embodiments, the targeting ligand is attached to the oxygen atom at the 5' position of the 5' end nucleotide of the oligonucleotide.

[0024] In some embodiments, the targeting group is attached to the compound or a salt thereof of any of the foregoing embodiments via a connector. The reactive group used to attach the targeting group is, for example, an amino group (also referred to herein as an amine), a phosphate ester group, or a thiophosphate ester group. The reactive group can be used to subsequently attach the targeting group using methods typical in the art.

[0025] In some embodiments, the compounds of the present invention are selected from any of the compounds shown in Table 3.

[0026] In some embodiments, the compounds of the present invention are selected from the compounds shown in SEQ ID NO: 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200.

[0027] On the other hand, the present invention provides a composition comprising a first compound or a salt thereof, and a pharmaceutically acceptable carrier, wherein the first compound is a compound of any of the foregoing embodiments.

[0028] In some embodiments, pharmaceutically acceptable carriers may be used to deliver the compounds of the present invention, or salts thereof, to cells or tissues. Pharmaceutically acceptable carriers are compounds that improve the delivery of RNAi constructs to cells or tissues. Pharmaceutically acceptable carriers may include, but are not limited to, polymers (such as amphiphilic polymers), membrane-active polymers, peptides, melittin peptides, melittin-like peptides (MLPs), lipids, reversibly modified polymers or peptides or reversibly modified membrane-active polyamines, or combinations thereof. In some embodiments, the compounds of the present invention, or salts thereof, may be combined with lipids, nanoparticles, polymers, liposomes, micelles, DPCs, or other delivery systems available in the art.

[0029] In some embodiments, the pharmaceutical composition of the present invention further comprises a second compound or a salt thereof, or one or more other therapeutic agents. The second compound is selected from any of the foregoing embodiments other than the first compound.

[0030] On the other hand, the present invention provides a method for preventing, treating, or alleviating a disease or symptom, the method comprising administering to a subject in need an effective amount of a compound of any of the foregoing embodiments or a salt thereof, or a composition of any of the foregoing embodiments. Preferably, the disease or symptom is a PKK-related disease or symptom.

[0031] On the other hand, the present invention provides the use of compounds of any of the foregoing embodiments or salts thereof, or compositions of any of the foregoing embodiments, in the preparation of medicaments for the prevention, treatment, or alleviation of diseases or symptoms. Preferably, the disease or symptom is a PKK-related disease or symptom.

[0032] On the other hand, the present invention provides the use of compounds or salts thereof, or compositions thereof, from any of the foregoing embodiments for the prevention, treatment, or alleviation of diseases or symptoms. Preferably, the diseases or symptoms are PKK-related diseases or symptoms.

[0033] On the other hand, the present invention provides the use of compounds of any of the foregoing embodiments or salts thereof or compositions of any of the foregoing embodiments in inhibiting PKK mRNA and / or protein expression.

[0034] In some embodiments, the compounds of the present invention, or salts thereof, compositions, and methods thereof, reduce target mRNA levels in cells, cell populations, tissues, or subjects, including by administering a therapeutically effective amount of the compounds described herein or salts thereof to the subject, thereby inhibiting PKK mRNA expression in the subject. In some embodiments, the subject has previously been identified as having upregulated pathogenicity of a target gene in cells or tissues to which it is targeted.

[0035] In some embodiments, the disease or symptom is edema, swelling, thrombosis, embolism, or occlusion. Preferably, in some embodiments, the edema is ocular edema, macular edema, or cerebral edema. Preferably, in some embodiments, the thrombosis is deep vein thrombosis. Preferably, in some embodiments, the embolism is pulmonary embolism. Preferably, in some embodiments, the occlusion is myocardial infarction or stroke.

[0036] In some embodiments, the disease or symptom is angioedema. Preferably, in some embodiments, the angioedema is hereditary angioedema (HAE). The compounds of the present invention or salts thereof comprise oligomeric compounds or salts thereof that hybridize with target nucleic acids, including but not limited to oligonucleotides, siRNA, shRNA, and ssRNA. Detailed Implementation

[0037] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are one module embodiment of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0038] Example 1

[0039] General methods for preparing Gap antisense oligonucleotides using solid-phase technology

[0040] Unless otherwise stated, all reagents and solutions used in the synthesis of oligomers were purchased from commercial sources. Standard phosphoramide structural units and solid supports were used to incorporate nucleoside residues, including, for example, T, A, G, and... m C residues. The phosphoramidite solutions of the monomers β-D-2'-deoxyribonucleoside and β-D-2'-(MOE)ribonucleoside were both 0.06 M solutions in anhydrous acetonitrile, and the phosphoramidite solution of 4'-CH(CH3)-O-2' (when in the S configuration, referred to as "cEt")ribonucleoside was a 0.1 M solution in anhydrous acetonitrile.

[0041] A 500 nmol synthesis column made of Universal CPG solid support was packed into an LK-48E synthesizer, and the specified sequence was synthesized using a phosphorus amide coupling method. For the coupling step, DNA and MOE phosphorus amide monomers were delivered in an amount more than four times the loading on the solid support and phosphorus amide condensation was performed for 10 min; cEt phosphorus amide monomers were delivered in an amount more than four times the loading on the solid support and phosphorus amide condensation was performed for 20 min. All other steps were performed according to the manufacturer's standard protocol. Dimethoxytriphenylmethyl (DMT) was removed from the 5'-hydroxyl group of the nucleotide using a solution of 3% trichloroacetic acid in dichloromethane. BTT (0.35 M, containing 0.5% NMI) in anhydrous acetonitrile was used as an activator in the coupling step. Phosphothiophosphate bonding was introduced by a contact time of 3 min with a 0.2 M solution of diphenylacetyl disulfide in 1:1 pyridine / acetonitrile.

[0042] After the specified sequence was synthesized, the specified sequence bound to the solid support was suspended in ammonia (25wt%-30wt%) and heated at 85°C for 2 h. The solid support was then filtered off and the ammonia was removed under reduced pressure. The residue was purified by high-performance liquid chromatography to prepare the Gap antisense oligonucleotides shown in Table 1.

[0043] The Gap antisense oligonucleotides in Table 1 were designed as 5-10-5 MOE spacers, 4-8-4 MOE spacers, 4-9-4 MOE spacers, 3-8-4 MOE spacers, 4-9-5 MOE spacers, 4-10-4 MOE spacers, 5-9-5 MOE spacers, 3-10-3 cEt spacers, 3-8-3 cEt spacers, 3-9-3 cEt spacers, 3-7-3 cEt spacers, and 5-4-1-5-5 MOE double spacers. Spacer, 3-2-10-1-4 MOE / cEt spacer, 4-1-10-5 MOE / cEt spacer, 4-1-10-1-4 MOE / cEt spacer, 2-3-10-1-4 MOE / cEt spacer, 3-1-8-1-3 MOE / cEt spacer, 2-2-8-2-2 MOE / cEt spacer, 3-2-10-5 MOE / cEt spacer, 2-1-10-2-1 MOE / cEt spacer.

[0044] The 5-10-5 MOE spacer is 20 nucleotides long, with the central spacer containing 10 2'-deoxynucleotides and flanked by wings containing 5 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with MOE sugar.

[0045] The 4-8-4 MOE spacer is 16 nucleotides long, with the central spacer containing 8 2'-deoxynucleotides and flanked by wings containing 4 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with MOE sugar.

[0046] The 4-9-4 MOE spacer is 17 nucleotides long, with the central spacer containing 9 2'-deoxynucleotides and flanked by wings containing 4 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with MOE sugar.

[0047] The 3-8-4MOE spacer is 15 nucleotides long, with the central spacer containing 8 2'-deoxynucleotides and flanked by wings containing 3 and 4 nucleotides respectively in the 5' and 3' directions. Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with MOE sugar.

[0048] The 4-9-5MOE spacer has a length of 18 nucleotides, with the central spacer containing 9 2'-deoxynucleotides and flanked by wings containing 4 and 5 nucleotides respectively in the 5' and 3' directions. Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with MOE sugar.

[0049] The 4-10-4 MOE spacer has a length of 18 nucleotides, with the central spacer containing 10 2'-deoxynucleotides and flanked by wings containing 4 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with MOE sugars.

[0050] The 5-9-5 MOE spacer is 19 nucleotides long, with the central spacer containing 9 2'-deoxynucleotides and flanked by wings containing 5 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with MOE sugar.

[0051] The 3-10-3cEt spacer is 16 nucleotides long, with the central spacer containing 10 2'-deoxynucleotides and flanked by wings containing 3 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with cEt sugar.

[0052] The 3-8-3cEt spacer is 14 nucleotides long, with the central spacer containing 8 2'-deoxynucleotides and flanked by wings containing 3 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with cEt sugar.

[0053] The 3-9-3cEt spacer is 15 nucleotides long, with the central spacer containing 9 2'-deoxynucleotides and flanked by wings containing 3 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with cEt sugar.

[0054] The 3-7-3cEt spacer is 13 nucleotides long, with the central spacer containing 7 2'-deoxynucleotides and flanked by wings containing 3 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with cEt sugar.

[0055] The 5-4-1-5-5 MOE double spacer has a length of 20 nucleotides, of which the central spacer (from 5' to 3') contains 4 consecutive 2'-deoxy nucleotides, 1 MOE sugar-modified nucleotide, and 5 consecutive 2'-deoxy nucleotides; the 5' wing (from 5' to 3') contains 5 consecutive MOE sugar-modified nucleotides; and the 3' wing (from 5' to 3') contains 5 consecutive MOE sugar-modified nucleotides.

[0056] The 3-2-10-1-4MOE / cEt spacer has a length of 20 nucleotides, with the central spacer containing 10 2'-deoxy nucleotides, the 5' wing (from 5' to 3') containing 3 consecutive MOE sugar-modified nucleotides and 2 consecutive cEt sugar-modified nucleotides flanked by the wing, and the 3' wing (from 5' to 3') containing 1 cEt sugar-modified nucleotide and 4 consecutive MOE sugar-modified nucleotides flanked by the wing.

[0057] The 4-1-10-5MOE / cEt spacer has a length of 20 nucleotides, with the central spacer containing 10 2'-deoxy nucleotides, the 5' wing (from 5' to 3') containing 4 consecutive MOE sugar-modified nucleotides and 1 cEt sugar-modified nucleotide, and the 3' wing (from 5' to 3') containing 5 consecutive MOE sugar-modified nucleotides.

[0058] The 4-1-10-1-4MOE / cEt spacer has a length of 20 nucleotides, with the central spacer containing 10 2'-deoxy nucleotides, the 5' wing segment (from 5' to 3') containing 4 consecutive MOE sugar-modified nucleotides and 1 cEt sugar-modified nucleotide, and the 3' wing segment (from 5' to 3') containing 1 cEt sugar-modified nucleotide and 4 consecutive MOE sugar-modified nucleotides.

[0059] The 2-3-10-1-4MOE / cEt spacer has a length of 20 nucleotides, with the central spacer containing 10 2'-deoxy nucleotides, the 5' wing (from 5' to 3') containing 2 consecutive MOE sugar-modified nucleotides and 3 consecutive cEt sugar-modified nucleotides, and the 3' wing (from 5' to 3') containing 1 cEt sugar-modified nucleotide and 4 consecutive MOE sugar-modified nucleotides.

[0060] The 3-1-8-1-3MOE / cEt spacer has a length of 16 nucleotides, with the central spacer containing 8 2'-deoxy nucleotides, the 5' wing (from 5' to 3') containing 3 consecutive MOE sugar-modified nucleotides and 1 cEt sugar-modified nucleotide, and the 3' wing (from 5' to 3') containing 1 cEt sugar-modified nucleotide and 3 consecutive MOE sugar-modified nucleotides.

[0061] The 2-2-8-2-2MOE / cEt spacer has a length of 16 nucleotides, with the central spacer containing 8 2'-deoxy nucleotides, the 5' wing (from 5' to 3') containing 2 consecutive MOE sugar-modified nucleotides and 2 consecutive cEt sugar-modified nucleotides flanked by the wing, and the 3' wing (from 5' to 3') containing 2 consecutive cEt sugar-modified nucleotides and 2 consecutive MOE sugar-modified nucleotides flanked by the wing.

[0062] The 3-2-10-5MOE / cEt spacer has a length of 20 nucleotides, with the central spacer containing 10 2'-deoxy nucleotides, the 5' wing (from 5' to 3') containing 3 consecutive MOE sugar-modified nucleotides and 2 consecutive cEt sugar-modified nucleotides, and the 3' wing (from 5' to 3') containing 5 consecutive MOE sugar-modified nucleotides.

[0063] The 2-1-10-2-1 MOE / cEt spacer has a length of 16 nucleotides, with the central spacer containing 10 2'-deoxy nucleotides, the 5' wing (from 5' to 3') containing two consecutive MOE sugar-modified nucleotides and one cEt sugar-modified nucleotide, and the 3' wing (from 5' to 3') containing two consecutive cEt sugar-modified nucleotides and one MOE sugar-modified nucleotide.

[0064] Throughout the spacer, except for those marked with PO and MsPA modifications, all other nucleoside internucleotide bonds are phosphate thioester (P=S) bonds. All cytosine residues within the spacer are 5-methylcytosine.

[0065] The sequences of this invention all target the human KLKB1 genome sequence (Genbank accession number NG_012095.2, https: / / www.ncbi.nlm.nih.gov / nuccore / NG_012095.2?report=fasta).

[0066] Table 1. Preparation of Gap antisense oligonucleotides using solid-phase technology

[0067] Example 2

[0068] General methods for preparing PO or MsPA-modified Gap antisense oligonucleotides using solid-phase techniques

[0069] Unless otherwise stated, all reagents and solutions used in the synthesis of oligomers were purchased from commercial sources. Standard phosphoramide structural units and solid supports were used to incorporate nucleoside residues, including, for example, T, A, G, and... m C residues. The phosphoramidite solutions of the monomers β-D-2'-deoxyribonucleoside and β-D-2'-(MOE)ribonucleoside were both 0.06 M solutions in anhydrous acetonitrile, and the phosphoramidite solution of 4'-CH(CH3)-O-2' (when in the S configuration, referred to as "cEt")ribonucleoside was a 0.1 M solution in anhydrous acetonitrile.

[0070] A 500 nmol synthesis column made of Universal CPG solid support was packed into an LK-48E synthesizer, and the specified sequence was synthesized using a phosphorus amide coupling method. For the coupling step, DNA and MOE phosphorus amide monomers were delivered in an amount more than four times the loading on the solid support and phosphorus amide condensation was performed for 10 min; cEt phosphorus amide monomers were delivered in an amount more than four times the loading on the solid support and phosphorus amide condensation was performed for 20 min. All other steps were performed according to the manufacturer's standard protocol. Dimethoxytriphenylmethyl (DMT) was removed from the 5'-hydroxyl group of the nucleotide using a solution of 3% trichloroacetic acid in dichloromethane. BTT (0.35 M, containing 0.5% NMI) in anhydrous acetonitrile was used as an activator in the coupling step. Phosphothiophosphate bonding was introduced by a contact time of 3 min with a 0.2 M solution of diphenylacetyl disulfide in 1:1 pyridine / acetonitrile. Phosphate ester bonds were introduced by oxidation with I2 in a 0.05M solution of THF / pyridine for 2 minutes. Methanesulfonyl-aminophosphate (MsPA) bonds were introduced by reaction with methanesulfonyl azide (MsN3) in a 1M solution of acetonitrile for 2 minutes.

[0071] After the specified sequence was synthesized, the specified sequence bound to the solid support was suspended in ammonia (25wt%-30wt%) and heated at 85°C for 2 h. The solid support was then filtered off and the ammonia was removed under reduced pressure. The residue was purified by high-performance liquid chromatography to prepare PO or MsPA-modified Gap antisense oligonucleotides as shown in Table 2.

[0072] The Gap antisense oligonucleotides in Table 2 were designed as 5-10-5 MOE spacers and 3-10-3 cEt spacers.

[0073] The 5-10-5 MOE spacer is 20 nucleotides long, with the central spacer containing 10 2'-deoxynucleotides and flanked by wings containing 5 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with MOE sugar.

[0074] The 3-10-3cEt spacer is 16 nucleotides long, with the central spacer containing 10 2'-deoxynucleotides and flanked by wings containing 3 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with cEt sugar.

[0075] The lowercase letter 'o' indicates that the bond between adjacent nucleosides is a phosphate ester (PO). The lowercase letter 'u' indicates that the bond between adjacent nucleosides is a methanesulfonyl-aminophosphate (MsPA), and all other inter-nucleoside bonds are thiophosphate (P=S) bonds. All cytosine residues within the entire spacer are 5-methylcytosine. Methanesulfonyl-aminophosphate has the following group:

[0076] Table 2. Preparation of PO or MsPA-modified Gap antisense oligonucleotides using solid-phase technology

[0077] Example 3

[0078] General methods for preparing 5'GalNAc-conjugated Gap antisense oligonucleotides using solid-phase technology

[0079] Unless otherwise stated, all reagents and solutions used in the synthesis of oligomers were purchased from commercial sources. Standard phosphoramide structural units and solid supports were used to incorporate nucleoside residues, including, for example, T, A, G, and... m C residues. The 5'-terminal phosphodiester-linked GalNAc conjugate was synthesized using the 59GN3 phosphoramidide compound (0.1 M). The phosphoramidide solutions of the monomers β-D-2'-deoxyribonucleoside and β-D-2'-(MOE)ribonucleoside were both 0.06 M in anhydrous acetonitrile, and the phosphoramidide solution of 4'-CH(CH3)-O-2' (referred to as "cEt" when in the S configuration) ribonucleoside was 0.1 M in anhydrous acetonitrile.

[0080] A 500 nmol synthesis column made of Universal CPG solid support was packed into an LK-48E synthesizer, and the specified sequence was synthesized using a phosphorus amide coupling method. For the coupling step, DNA and MOE phosphorus amide monomers were delivered in an amount more than four times the loading on the solid support and phosphorus amide condensation was performed for 10 min; cEt phosphorus amide monomers were delivered in an amount more than four times the loading on the solid support and phosphorus amide condensation was performed for 20 min. All other steps were performed according to the manufacturer's standard protocol. Dimethoxytriphenylmethyl (DMT) was removed from the 5'-hydroxyl group of the nucleotide using a solution of 3% trichloroacetic acid in dichloromethane. BTT (0.35 M, containing 0.5% NMI) in anhydrous acetonitrile was used as an activator in the coupling step. Phosphothiophosphate bonding was introduced by a contact time of 3 min with a 0.2 M solution of diphenylacetyl disulfide in 1:1 pyridine / acetonitrile. Phosphate ester bonds were introduced by oxidation with I2 in a 0.05M solution of THF / pyridine for 2 minutes. Methanesulfonyl-aminophosphate (MsPA) bonds were introduced by reaction with methanesulfonyl azide (MsN3) in a 1M solution of acetonitrile for 2 minutes.

[0081] After the specified sequence was synthesized, the specified sequence bound to the solid support was suspended in ammonia (25wt%-30wt%) and heated at 85°C for 2 h. The solid support was then filtered off and the ammonia was removed under reduced pressure. The residue was purified by high-performance liquid chromatography to prepare the Gap antisense oligonucleotides shown in Table 3.

[0082] The Gap antisense oligonucleotides in Table 3 were designed as 5-10-5 MOE spacers, 3-10-3 cEt spacers, 3-9-3 cEt spacers, 3-7-3 cEt spacers, 2-2-8-2-2 MOE / cEt spacers, and 3-2-10-1-4 MOE / cEt spacers.

[0083] The 5-10-5 MOE spacer is 20 nucleotides long, with the central spacer containing 10 2'-deoxynucleotides and flanked by wings containing 5 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with MOE sugar.

[0084] The 3-10-3cEt spacer is 16 nucleotides long, with the central spacer containing 10 2'-deoxynucleotides and flanked by wings containing 3 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with cEt sugar.

[0085] The 3-9-3cEt spacer is 15 nucleotides long, with the central spacer containing 9 2'-deoxynucleotides and flanked by wings containing 3 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with cEt sugar.

[0086] The 3-7-3cEt spacer is 13 nucleotides long, with the central spacer containing 7 2'-deoxynucleotides and flanked by wings containing 3 nucleotides each on both sides (in the 5' and 3' directions). Each nucleotide in the 5' wing and each nucleotide in the 3' wing are modified with cEt sugar.

[0087] The 2-2-8-2-2MOE / cEt spacer has a length of 16 nucleotides, with the central spacer containing 8 2'-deoxy nucleotides, the 5' wing (from 5' to 3') containing 2 consecutive MOE sugar-modified nucleotides and 2 consecutive cEt sugar-modified nucleotides flanked by the wing, and the 3' wing (from 5' to 3') containing 2 consecutive cEt sugar-modified nucleotides and 2 consecutive MOE sugar-modified nucleotides flanked by the wing.

[0088] The 3-2-10-1-4MOE / cEt spacer has a length of 20 nucleotides, with the central spacer containing 10 2'-deoxy nucleotides, the 5' wing (from 5' to 3') containing 3 consecutive MOE sugar-modified nucleotides and 2 consecutive cEt sugar-modified nucleotides flanked by the wing, and the 3' wing (from 5' to 3') containing 1 cEt sugar-modified nucleotide and 4 consecutive MOE sugar-modified nucleotides flanked by the wing.

[0089] The lowercase letter 'o' indicates that the bond between adjacent nucleosides is a phosphate ester (PO). The lowercase letter 'u' indicates that the bond between adjacent nucleosides is a methanesulfonyl-aminophosphate (MsPA), and the nucleosides in other positions are thiophosphate (P=S) bonds. All cytosine residues in the entire spacer are 5-methylcytosine (5-mC). Methanesulfonyl-aminophosphate has the following groups:

[0090] THAGN3 has groups of the following formula:

[0091] 59GN3 has the following groups:

[0092] Table 3. Preparation of 5'GalNAc-conjugated Gap antisense oligonucleotides using solid-phase technology

[0093] Example 4. Transfection of 100 nM antisense oligonucleotides into Huh-7 cells resulted in the antisense inhibition of KLKB1 gene expression by the antisense oligonucleotides.

[0094] Design antisense oligonucleotides targeting KLKB1 nucleic acid and test their effects on KLKB1 mRNA in vitro.

[0095] Huh-7 cells were seeded in 24-well plates at a density of 1.2 x 10⁶ cells per well. 5 Cells were transfected with 100 nM different antisense oligonucleotides into the corresponding wells using a Beyotime calcium phosphate transfection kit after 18 hours. The blank control group was transfected with DEPC water. After culturing at 37°C and 5% CO2 for another 24 hours, cells were treated with Trizol (Invitrogen) to extract RNA. The obtained RNA was used as a template for reverse transcription using MMLV reverse transcriptase (Promega) to obtain cDNA. Subsequently, using cDNA as a template, the human KLKB1 mRNA level was detected by real-time quantitative PCR using the human KLKB1 primer set (forward sequence TCGGACCATCTGCACCTATC, designated as SEQ ID NO:172; reverse sequence TGCAGGTTAAAAGGCTATATCCA, designated as SEQ ID NO:173), with GAPDH as an internal reference gene (forward sequence GTCTCCTCTGACTTCAACAGCG, designated as SEQ ID NO:174; reverse sequence ACCACCCTGTTGCTGTAGCCAA, designated as SEQ ID NO:175). Data analysis was performed using the 2^-ΔΔCT method. The inhibition rate (%) of each oligonucleotide at a 100 nM transfection concentration was calculated compared to the cell group treated with DEPC water.

[0096] Table 4. Effect of 100 nM antisense oligonucleotide transfection on human KLKB1 gene knockdown in Huh-7 cells

[0097] Note: When the inhibition rate in the table is negative, the value indicates the degree of gene expression upregulation.

[0098] Example 5. Transfection of 50 nM antisense oligonucleotides into Huh-7 cells resulted in antisense repression of human KLKB1 gene expression by the antisense oligonucleotides.

[0099] Design antisense oligonucleotides targeting KLKB1 nucleic acid and test their effects on KLKB1 mRNA in vitro.

[0100] Huh-7 cells were seeded in 24-well plates at a density of 1.2 x 10⁶ cells per well. 5Cells were transfected with 50 nM different antisense oligonucleotides into the corresponding wells using a calcium phosphate transfection kit (Beyotime) after 18 hours. The blank control group was transfected with DEPC water. After culturing at 37°C and 5% CO2 for another 24 hours, the cells were treated with Trizol (Invitrogen) to extract RNA. The obtained RNA was used as a template for reverse transcription using MMLV reverse transcriptase (Promega) to obtain cDNA. Subsequently, using cDNA as a template, the human KLKB1 mRNA level was detected by real-time quantitative PCR using the human KLKB1 primer set (forward sequence TCGGACCATCTGCACCTATC, designated as SEQ ID NO:172; reverse sequence TGCAGGTTAAAAGGCTATATCCA, designated as SEQ ID NO:173), with human GAPDH as an internal reference gene (forward sequence GTCTCCTCTGACTTCAACAGCG, designated as SEQ ID NO:174; reverse sequence ACCACCCTGTTGCTGTAGCCAA, designated as SEQ ID NO:175). Data analysis was performed using the 2^-ΔΔCT method. The inhibition rate (%) of each oligonucleotide at a 50 nM transfection concentration on human KLKB1 mRNA was calculated compared with that of cells treated with DEPC water.

[0101] Table 5. Effect of 50 nM antisense oligonucleotide transfection on human KLKB1 gene knockdown in Huh-7 cells

[0102] Note: When the inhibition rate in the table is negative, the value indicates the degree of gene expression upregulation.

[0103] Example 6. Transfection of 20 nM antisense oligonucleotides into Huh-7 cells resulted in antisense repression of the human KLKB1 gene by the antisense oligonucleotides.

[0104] Design antisense oligonucleotides targeting KLKB1 nucleic acid and test their effects on KLKB1 mRNA in vitro.

[0105] Huh-7 cells were seeded in 24-well plates at a density of 1.2 x 10⁶ cells per well. 5Cells were transfected with 20 nM different antisense oligonucleotides into the corresponding wells using a calcium phosphate transfection kit (Beyotime) after 18 hours. The blank control group was transfected with DEPC water. After culturing at 37°C and 5% CO2 for another 24 hours, the cells were treated with Trizol (Invitrogen) to extract RNA. The obtained RNA was used as a template for reverse transcription using MMLV reverse transcriptase (Promega) to obtain cDNA. Subsequently, using cDNA as a template, the human KLKB1 mRNA level was detected by real-time quantitative PCR using the human KLKB1 primer set (forward sequence TCGGACCATCTGCACCTATC, designated as SEQ ID NO:172; reverse sequence TGCAGGTTAAAAGGCTATATCCA, designated as SEQ ID NO:173), with GAPDH as an internal reference gene (forward sequence GTCTCCTCTGACTTCAACAGCG, designated as SEQ ID NO:174; reverse sequence ACCACCCTGTTGCTGTAGCCAA, designated as SEQ ID NO:175). Data analysis was performed using the 2^-ΔΔCT method. The inhibition rate (%) of each oligonucleotide at a 20 nM transfection concentration on human KLKB1 mRNA was calculated compared with that of cells treated with DEPC water.

[0106] Table 6. Effect of 20 nM antisense oligonucleotide transfection on human KLKB1 gene knockdown in Huh-7 cells

[0107] Note: When the inhibition rate in the table is negative, the value indicates the degree of gene expression upregulation.

[0108] SEQ ID NO:148-149 and SEQ ID NO:152-153 and 155 in Table 6 above are comparative sequence sequences. Specific sequence information is shown in Table 7. The above sequences can be prepared by referring to the preparation method of Example 1.

[0109] Table 7. Sequence information of SEQ ID NO: 148-149, 152-153 and 155

[0110] Example 7. In Huh-7 cells, human KLKB1 was inhibited by antisense oligonucleotides at concentration gradients in a concentration-dependent manner.

[0111] Design antisense oligonucleotides targeting KLKB1 nucleic acid and test their effects on KLKB1 mRNA in vitro.

[0112] Huh7 cells were seeded in 24-well plates at a density of 1.2 x 10⁶ cells per well.5 Cells were transfected with different antisense oligonucleotides into the corresponding wells using a Beyotime calcium phosphate transfection kit after 18 hours. Each oligonucleotide was transfected at five concentration gradients: 0.5 nM, 1.5 nM, 5 nM, 15 nM, and 50 nM; or five concentration gradients: 1.5 nM, 5 nM, 15 nM, 44 nM, and 134 nM; or five concentration gradients: 0.2 nM, 0.6 nM, 2 nM, 6 nM, and 20 nM. The blank control group was transfected with DEPC water. After culturing at 37°C and 5% CO2 for 24 hours, cells were treated with Trizol (Invitrogen) to extract RNA. The obtained RNA was used as a template for reverse transcription using mmLV reverse transcriptase (Promega) to obtain cDNA. Subsequently, using cDNA as a template, the human KLKB1 mRNA level was detected by real-time quantitative PCR using the human KLKB1 primer set (forward sequence TCGGACCATCTGCACCTATC, designated as SEQ ID NO:172 in this paper; reverse sequence TGCAGGTTAAAAGGCTATATCCA, designated as SEQ ID NO:173 in this paper), with GAPDH as an internal reference gene (forward sequence GTCTCCTCTGACTTCAACAGCG, designated as SEQ ID NO:174 in this paper; reverse sequence ACCACCCTGTTGCTGTAGCCAA, designated as SEQ ID NO:175 in this paper). Data analysis was performed using the 2^-ΔΔCT method. The water-treated cell group served as a blank control. The percentage of residual activity in the ASO-treated group (%) was calculated as (ASO / Control) × 100%, and the IC50 value was calculated based on the percentage of residual activity at different concentrations. IC50 uses the following model and calculation formula: log(inhibitor) vs. response -- Variable slope (four parameters) and Y = Bottom + (Top - Bottom) / (1 + 10^((LogIC50 - X) * HillSlope)). Test results are shown in Table 8.

[0113] Table 8. Effects of antisense oligonucleotides on knockdown of human KLKB1 gene

[0114] Example 8. Pharmacological effects of antisense oligonucleotide (ASO) sequences in mice.

[0115] Using PBS as a negative control, the in vivo efficacy of the antisense oligonucleotides studied above was evaluated in C57BL6 / J mice via intraperitoneal injection.

[0116] Multiple groups of mice were intraperitoneally injected with different antisense oligonucleotides at doses of 10 mg / kg, 20 mg / kg, or 50 mg / kg. The mice were euthanized 3 or 7 days after the injection, and liver organs and serum were collected for further analysis.

[0117] To evaluate the effects of antisense oligonucleotides on the reduction of target mRNA and protein, RNA was extracted from liver tissue for quantitative real-time PCR analysis of KLKB1 mRNA. Alternatively, Western blotting and grayscale quantification of protein were used to analyze serum PKK protein. Data were presented as inhibition rates of KLKB1 mRNA and PKK protein, with the PBS group serving as a control. Specific steps are as follows:

[0118] (1) C57BL6 / J male mice, 8-10 weeks old, were enrolled in groups according to their body weight, with 3-4 mice in each group;

[0119] (2) Preparation of ASO solution: Dissolve ASO in PBS, measure and correct the concentration using a Nanodrop micro-nucleic acid protein analyzer, and adjust the concentration of the stock solution to 1.8±10% mg / mL. The prepared ASO can be stored at -80℃ or used directly in subsequent experiments.

[0120] (3) Intraperitoneal injection of ASO: Weigh the mice and administer ASO according to their weight; grasp the skin on the back of the neck of the mouse, turn it so that its abdomen is facing up and its tail is facing the operator, gently pull the hind limbs to fix it, expose the lower abdomen, find the position slightly to the left of the midline of the lower abdomen of the mouse, and draw up the corresponding volume of ASO according to the specific working dose for intraperitoneal injection of the mouse.

[0121] (4) Three or seven days after ASO injection, mice were sacrificed, dissected, and liver tissue was collected for RNA extraction and stored in trizol lysis buffer; serum was collected for protein detection.

[0122] (5) Add two stainless steel beads to the liver tissue sample and homogenize the liver tissue sample thoroughly using a grinder (SCIENTZ, SCIENTZ-48) at 60 Hz for 30 seconds for 3 cycles. Let it stand at room temperature for 5 minutes.

[0123] (6) RNA was extracted from liver tissue according to the kit (Tiangen, DP419); the obtained RNA solution was stored at -80℃ or used for subsequent experiments.

[0124] (7) Reverse transcription: Reverse transcription was performed using the EZBioscience B0003 kit.

[0125] (8) qPCR detection was performed using the ABI QuantStudio 3 system. The qPCR reaction system was 20 μL per sample replicate. The qPCR reaction system preparation consisted of 10 μL 2X SYBR Green qPCR master mix + 1 μL cDNA + 0.4 μL Forward primer (10 μM) + 0.4 μL Reverse primer (10 μM) + 8.2 μL dd H2O. The qPCR results were analyzed, and the KLKB1 gene mRNA expression levels in different treatment groups were calculated. The knockdown effect of ASO on KLKB1 gene mRNA in vivo (KD%) was also calculated. The KLKB1 forward primer sequence CCTCCAGAACCACAACGTGA (mouse) is designated as SEQ ID NO:176 in this paper; the reverse primer sequence ATACACCCACAGGAGACGGTA (mouse) is designated as SEQ ID NO:177 in this paper. The forward primer sequence for the internal reference 18S rRNA is AGTCCCTGCCCTTTGTACACA, designated as SEQ ID NO:178 in this paper; the reverse primer sequence is CGATCCGAGGGCCTCACTA, designated as SEQ ID NO:179 in this paper.

[0126] (9) Serum samples were diluted 1:50 using RIPA solution (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM MgCl2, 1.5% NP-40, 0.1% SDS, and 0.5% sodium deoxycholate, with protease inhibitors added at the time of use: 1 mM phenylmethyl sulfonyl fluoride, 10 μM MG132, 10 μg / mL leupeptin, 5 μg / mL pepstatin, 25 μg / mL ALLN, and 1 mM dithiothreitol). The diluted serum samples were then added to one-third of a volume of 4× Loading solution (150 mM Tris-HCl, pH 6.8, 12% SDS, 30% glycerol, 6% 2-mercaptoethanol, and 0.02% bromophenol). After mixing, boil at 95°C for 10 minutes to prepare samples for protein gel electrophoresis and Western blotting hybridization. SDS-PAGE gel electrophoresis and membrane transfer were performed at a loading rate of 20 μL / well, followed by overnight incubation at 4°C with anti-PKK primary antibody (R&D, AF2498). For albumin detection, serum samples were diluted 1500-fold with anti-albumin primary antibody (abclonal, A24161). Subsequently, incubation with secondary antibody (Goat anti-rat or rabbit IgG (H+L) Secondary Antibody, HRP, Thermo Scientific). TM Finally, e-BLOT (Touch imager) was used for chemical exposure and imaging; based on the imaging data and the gray-scale quantification of protein bands, the expression level of PKK protein in different treatment groups was calculated, and the knockdown effect (KD%) of ASO on PKK protein in vivo was calculated.

[0127] Experimental results show that the ASO sequence of the present invention can significantly inhibit the expression levels of KLKB1 mRNA and PKK protein in mice.

[0128] Table 9. Effect of ASO intraperitoneal injection on KLKB1 mRNA knockdown in mice

[0129] Table 10. Effect of ASO intraperitoneal injection on KLKB1 mRNA knockdown in mice

[0130] Table 11. Knockdown effect of ASO intraperitoneal injection on PKK protein in mice

[0131] Note: When the inhibition rate in the table is negative, the value indicates the degree of gene expression upregulation.

[0132] Example 9. Pharmacodynamic experiment of the antisense oligonucleotide sequence of the coupled ligand (GalNAc-ASO) in hKLKB1 humanized mice.

[0133] The in vivo efficacy of the conjugated ligand ASO was evaluated in hKLKB1 humanized mice using PBS as a negative control and via subcutaneous injection.

[0134] Using a CRISPR-Cas9 system (construction services provided by Jicui Pharmaceutical Co., Ltd.), a gene fragment containing the human KLKB1 coding region (CDS) was inserted into a specific location in the mouse genome to obtain the hKLKB1 gene knock-in mouse strain (hKLKB1-KI mouse) for testing the in vivo efficacy of the conjugated ligand ASO. This strain stably expresses human KLKB1 coding region mRNA and human PKK protein, but does not express mouse KLKB1 mRNA and mouse PKK protein.

[0135] GalNAc-conjugated ASO was administered subcutaneously to hKLKB1-KI mice. One week after injection, the knockdown efficiency of hKLKB1 mRNA and human PKK protein in the mouse liver was measured. The specific steps are as follows:

[0136] (1) hKLKB1-KI mice, 12-16 weeks old, were enrolled in groups according to their weight, with 3-4 mice in each group;

[0137] (2) Preparation of GalNAc-ASO solution: Add PBS to dissolve GalNAc-ASO, measure the concentration using a Nanodrop micro-nucleic acid protein analyzer and correct it, and adjust the concentration of the stock solution to 1.8±10% mg / mL. The prepared GalNAc-ASO can be stored at -80℃ or used directly in subsequent experiments.

[0138] (3) Subcutaneous injection of GalNAc-ASO: Weigh the mice and administer GalNAc-ASO according to their weight; Grasp the skin on the back of the neck of the mouse, lift and fix it, so that the mouse is facing downwards, find the loose skin on the back of the neck or side of the mouse, pinch the skin with your thumb and forefinger to form a "tent" shaped gap, and draw up the corresponding volume of ASO according to the specific working dose for subcutaneous injection.

[0139] (4) Seven days after GalNAc-ASO injection, mice were sacrificed, dissected, and liver tissue was collected for RNA extraction and stored in trizol lysis buffer; serum was collected for protein detection.

[0140] (5) Add two stainless steel beads to the liver tissue sample and homogenize the liver tissue sample thoroughly using a grinder (SCIENTZ, SCIENTZ-48) at 60 Hz for 30 seconds for 3 cycles. Let it stand at room temperature for 5 minutes.

[0141] (6) RNA was extracted from liver tissue according to the kit (Tiangen, DP419); the obtained RNA solution was stored at -80℃ or used for subsequent experiments.

[0142] (7) Reverse transcription: Reverse transcription was performed using the EZBioscience B0003 kit.

[0143] (8) qPCR detection was performed using the ABIQuantStudio 3 system. The qPCR reaction system was 20 μL per sample replicate. The qPCR reaction system preparation consisted of 10 μL 2X SYBR Green qPCR master mix + 1 μL cDNA + 0.4 μL Forward primer (10 μM) + 0.4 μL Reverse primer (10 μM) + 8.2 μL dd H2O. The qPCR results were analyzed, and the KLKB1 gene mRNA expression levels in different treatment groups were calculated. The knockdown effect (KD%) of GalNAc-ASO on KLKB1 gene mRNA in vivo was also calculated. The KLKB1 forward primer sequence ATAACCCAACGGATGGTCTGT (human) is designated as SEQ ID NO:201 in this study; the reverse primer sequence ACCACCTGAATCTCCCTTACA (human) is designated as SEQ ID NO:202 in this study. The forward primer sequence for the internal reference 18S rRNA is AGTCCCTGCCCTTTGTACACA, designated as SEQ ID NO:178 in this paper; the reverse primer sequence is CGATCCGAGGGCCTCACTA, designated as SEQ ID NO:179 in this paper.

[0144] (9) RIPA solution (50mM Tris-HCl, pH 8.0, 150mM NaCl, 2mM MgCl2, 1.5% NP-40, 0.1% SDS, and 0.5% sodium deoxycholate, with protease inhibitors added during use: 1mM phenylmethyl sulfonyl fluoride, 10μM MG132, 10μg / mL leupeptin, 5μg / mL pepstatin, 25μg / mL ALLN and 1mM dithiothreitol) was used to dilute the serum sample at a ratio of 1:50. The diluted serum sample was then added to one-third of the volume of 4×Loading solution (150mM Tris-HCl, pH 6.8, 12% SDS, 30% glycerol, 6% 2-mercaptoethanol and 0.02% bromophenol blue), mixed well, and boiled at 95°C for 10 minutes. Samples for protein gel electrophoresis and Western blotting were prepared. SDS-PAGE gel electrophoresis and membrane transfer were performed at a loading rate of 20 μL / well, followed by overnight incubation at 4°C with anti-PKK primary antibody (R&D, AF2498). For albumin detection, serum samples were diluted 1500-fold and incubated with anti-albumin primary antibody (abclonal, A24161). Subsequently, incubation with secondary antibody (Goat anti-rat or rabbit IgG (H+L) Secondary Antibody, HRP, Thermo Scientific). TM Finally, e-BLOT (Touch imager) was used for chemical exposure and imaging; based on the imaging data and the gray-scale quantification of protein bands, the expression level of PKK protein in different treatment groups was calculated, and the knockdown effect (KD%) of GalNAc-ASO on PKK protein in vivo was calculated.

[0145] Experimental results show that the GalNAc-ASO sequence of the present invention can significantly inhibit the expression levels of human KLKB1 mRNA and human PKK protein in mice.

[0146] Table 12. Knockdown effect of GalNAc-ASO subcutaneous injection on human KLKB1 mRNA and human PKK protein in mice.

[0147] Table 13. Knockdown effect of GalNAc-ASO subcutaneous injection on human KLKB1 mRNA and human PKK protein in mice.

[0148] Note: When the inhibition rate in the table is negative, the value indicates the degree of gene expression upregulation.

[0149] Table 14. Knockdown effect of GalNAc-ASO subcutaneous injection on human KLKB1 mRNA in mice

[0150] Example 10. Pharmacological effects of the antisense oligonucleotide sequence of the coupled ligand (GalNAc-ASO) in mice.

[0151] Using PBS as a negative control, C57BL6J mice were injected subcutaneously with GalNAc-conjugated ASO. One week after injection, the expression levels and knockdown efficiency of KLKB1 mRNA and PKK protein in the liver of the mice were measured to evaluate the in vivo efficacy of the conjugated ligand ASO. The specific steps are as follows:

[0152] (1) C57BL6 / J mice, 8-10 weeks old, were enrolled in groups according to their body weight, with 3-4 mice in each group;

[0153] (2) Preparation of GalNAc-ASO solution: Add PBS to dissolve GalNAc-ASO, measure the concentration using a Nanodrop micro-nucleic acid protein analyzer and correct it, and adjust the concentration of the stock solution to 1.8±10% mg / mL. The prepared GalNAc-ASO can be stored at -80℃ or used directly in subsequent experiments.

[0154] (3) Subcutaneous injection of GalNAc-ASO: Weigh the mice and administer GalNAc-ASO according to their weight; Grasp the skin on the back of the neck of the mouse, lift and fix it, so that the mouse is facing downwards, find the loose skin on the back of the neck or side of the mouse, pinch the skin with your thumb and forefinger to form a "tent" shaped gap, and draw up the corresponding volume of ASO according to the specific working dose for subcutaneous injection.

[0155] (4) Seven days after GalNAc-ASO injection, mice were sacrificed, dissected, and liver tissue was collected for RNA extraction and stored in trizol lysis buffer; serum was collected for protein detection.

[0156] (5) Add two stainless steel beads to the liver tissue sample and homogenize the liver tissue sample thoroughly using a grinder (SCIENTZ, SCIENTZ-48) at 60 Hz for 30 seconds for 3 cycles. Let it stand at room temperature for 5 minutes.

[0157] (6) RNA was extracted from liver tissue according to the kit (Tiangen, DP419); the obtained RNA solution was stored at -80℃ or used for subsequent experiments.

[0158] (7) Reverse transcription: Reverse transcription was performed using the EZBioscience B0003 kit.

[0159] (8) qPCR detection was performed using the ABIQuantStudio 3 system. The qPCR reaction system was 20 μL per sample replicate. The qPCR reaction system preparation consisted of 10 μL 2X SYBR Green qPCR master mix + 1 μL cDNA + 0.4 μL Forward primer (10 μM) + 0.4 μL Reverse primer (10 μM) + 8.2 μL dd H2O. The qPCR results were analyzed, and the KLKB1 gene mRNA expression levels in different treatment groups were calculated. The knockdown effect (KD%) of GalNAc-ASO on KLKB1 gene mRNA in vivo was also calculated. The KLKB1 forward primer sequence CCTCCAGAACCACAACGTGA (mouse) is designated as SEQ ID NO:176 in this study; the reverse primer sequence ATACACCCACAGGAGACGGTA (mouse) is designated as SEQ ID NO:177 in this study. The forward primer sequence for the internal reference 18S rRNA is AGTCCCTGCCCTTTGTACACA, designated as SEQ ID NO:178 in this paper; the reverse primer sequence is CGATCCGAGGGCCTCACTA, designated as SEQ ID NO:179 in this paper.

[0160] (9) RIPA solution (50mM Tris-HCl, pH 8.0, 150mM NaCl, 2mM MgCl2, 1.5% NP-40, 0.1% SDS, and 0.5% sodium deoxycholate, with protease inhibitors added during use: 1mM phenylmethyl sulfonyl fluoride, 10μM MG132, 10μg / mL leupeptin, 5μg / mL pepstatin, 25μg / mL ALLN and 1mM dithiothreitol) was used to dilute the serum sample at a ratio of 1:50. The diluted serum sample was then added to one-third of the volume of 4×Loading solution (150mM Tris-HCl, pH 6.8, 12% SDS, 30% glycerol, 6% 2-mercaptoethanol and 0.02% bromophenol blue), mixed well, and boiled at 95°C for 10 minutes. Samples for protein gel electrophoresis and Western blotting were prepared. SDS-PAGE gel electrophoresis and membrane transfer were performed at a loading rate of 20 μL / well, followed by overnight incubation at 4°C with anti-PKK primary antibody (R&D, AF2498). For albumin detection, serum samples were diluted 1500-fold and incubated with anti-albumin primary antibody (abclonal, A24161). Subsequently, incubation with secondary antibody (Goat anti-rat or rabbit IgG (H+L) Secondary Antibody, HRP, Thermo Scientific). TM Finally, e-BLOT (Touch imager) was used for chemical exposure and imaging; based on the imaging data and the gray-scale quantification of protein bands, the expression level of PKK protein in different treatment groups was calculated, and the knockdown effect (KD%) of GalNAc-ASO on PKK protein in vivo was calculated.

[0161] Experimental results show that the GalNAc-ASO sequence of the present invention can significantly inhibit the expression levels of KLKB1 mRNA and PKK protein in mice.

[0162] Table 15. Knockdown effect of GalNAc-ASO subcutaneous injection on KLKB1 mRNA and PKK protein in mice.

[0163] Example 11. Liver toxicity assay of the antisense oligonucleotide sequence of the coupled ligand (GalNAc-ASO) in mice.

[0164] Using PBS as a negative control, C57BL6J mice or hKLKB1 humanized mice were injected subcutaneously with GalNAc-conjugated ASO (Seq ID NO: 180-200). One week after injection, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured to evaluate the hepatotoxicity of the conjugated ligand ASO. The specific steps are as follows:

[0165] (1) C57BL6 / J mice or hKLKB1 humanized mice, 8-10 weeks old, were enrolled according to their body weight; GalNAc-ASO was dissolved in PBS, and the concentration was measured and corrected by a Nanodrop micro-nucleic acid protein analyzer. The concentration of the stock solution was adjusted to 1.8±10% mg / mL. The prepared GalNAc-ASO could be stored at -80℃ or used directly for subsequent experiments; GalNAc-ASO subcutaneous injection: The mice were weighed and GalNAc-ASO was administered according to their body weight; The skin of the back of the neck of the mouse was grasped and gently lifted and fixed so that the mouse was abdomen down. The skin of the back of the neck or the side of the abdomen of the mouse was found to be loose. The skin was pinched with the thumb and forefinger to form a "tent"-shaped gap. The corresponding volume of ASO was drawn up according to the specific working dose and injected subcutaneously; Seven days after the GalNAc-ASO injection, the mice were sacrificed, dissected, and the mouse serum was collected for ALT AST detection. Test data show that GalNAc-ASO molecules with Seq ID NO: 181, 183, 187-189 and 194-199 have excellent liver safety.

Claims

1. A compound or a salt thereof comprising an oligonucleotide, said oligonucleotide being fully or partially complementary to at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides selected from the following regions of the KLKB1 genomic sequence NG_012095.2: 37945-37964, 44885-44904, 52611-52630, 32731-32750, 37946-37965, 51081-51100, 44406- 44425, 37947-37966, 44407-44426, 32864-32883, 30726-30745, 24266-24285, 48199-48218, 24265-24284, 54152-54171, 30725-30744, 29569-29588 51085-51104, 52612-52631, 29459-29478, 28176-28195, 52009-52028, 52010-52029, 52011-52030, 52013-52032, 52014-52033, 52015-52034, 5201 6-52035, 52059-52078, 52060-52079, 52061-52080, 47588-47607, 47590-47605, 28178-28194, 28179-28193, 52017-52034, 52025-52044, 52027-520 46, 53293-53312, 47506-47521, 46254-46269, 34348-34363, 29972-29987, 28178-28193, 52012-52027, 52017-52032, 54108-54123, 32953-32968, 54 105-54120, 52013-52028, 53293-53308, 53293-53307, 53293-53305, 31780-31795, 48197-48212, 30068-30083, 28177-28192, 52062-52077, 48198-4 8213, 52059-52074, 28176-28191, 54104-54119, 52065-52080, 28179-28194, 52019-52034, 52015-52032, 52016-52033, 52019-52032, 52019-52033,52019-52030, 52015-52033, 52015-52034; wherein the partial complementarity refers to 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides of the two sequences are complementary.

2. The compound or a salt thereof according to claim 1, wherein the region is selected from 37945-37964, 44885-44904, 52611-52630, 32731-32750, 53293-53308, 52019-52034, 53293-53308, 53293-53307, 53293-53305, 47588-47607, 47590-47605, 52019-52032, 52019-52030, 52015-52034, 28177-28192.

3. A compound or a salt thereof according to claim 1, comprising an oligonucleotide, the sequence of said oligonucleotide being a sequence of 12-23 consecutive nucleotides differing from any of the sequences shown in Table 1, Table 2 or Table 3 by 0, 1, 2, 3, 4 or 5 nucleotides.

4. The compound or its salt according to any one of claims 1 to 3, wherein at least one nucleotide of the oligonucleotide is a modified nucleotide and / or at least one nucleoside internucleotide is a modified nucleoside internucleotide.

5. The compound or a salt thereof according to claims 1 to 4, wherein the oligonucleotide comprises: i.5' wings, which are composed of 3, 4, 5 or 6 nucleotides linked together; ii. A central spacer segment, which consists of 7, 8, 9, 10 or 11 nucleotides linked together; iii. 3' Wing segment, which consists of 3, 4, 5 or 6 nucleotides linked together; The central spacer segment is located between the 5' wing segment and the 3' wing segment, and at least one nucleotide in the 5' wing segment and the 3' wing segment is a modified nucleotide or at least one nucleoside inter-bond is a modified nucleoside inter-bond.

6. The compound of claim 5 or a salt thereof, wherein all nucleotides in the 5' and 3' wings are modified nucleotides.

7. The compound or a salt thereof according to any one of claims 4 to 6, wherein the modifying group in the modified nucleotide is selected from one or more of 5-methylcytosine (5-mC), 2'-O-methoxyethyl (2'-MOE), 2'-O-alkyl, 2'-O-methyl, restricted ethyl (cEt), 3'-fluoro-HNA, LNA, 2'-fluoro, 2'-methoxyalkyl, 2'-O-allyl, 2'-C-allyl, BNA and THP; preferably 2'-O-methoxyethyl (2'-MOE) and restricted ethyl (cEt).

8. The compound of claim 5 or a salt thereof, wherein the nucleotides of the central spacer segment are all deoxyribonucleotides, or the nucleotides of the central spacer segment are a combination of deoxyribonucleotides and ribonucleotides.

9. The compound or a salt thereof according to any one of claims 4 to 8, wherein the modified nucleoside inter-bond is selected from one or more of phosphate ester bonds, thiophosphate ester bonds, and methanesulfonyl-aminophosphate ester bonds.

10. The compound according to any one of claims 4 to 9, or a salt thereof, wherein the modified structure of the oligonucleotide is selected from: 5-10-5 MOE spacers, 4-8-4 MOE spacers, 4-9-4 MOE spacers, 3-8-4 MOE spacers, 4-9-5 MOE spacers, 4-10-4 MOE spacers, 5-9-5 MOE spacers, 3-10-3 cEt spacers, 3-8-3 cEt spacers, 3-9-3 cEt spacers, 3-7-3 cEt spacers, 5- 4-1-5-5 MOE double spacer, 3-2-10-1-4 MOE / cEt spacer, 4-1-10-5 MOE / cEt spacer, 4-1-10-1-4 MOE / cEt spacer, 2-3-10-1-4 MOE / cEt spacer, 3-1-8-1-3 MOE / cEt spacer, 2-2-8-2-2 MOE / cEt spacer, 3-2-10-5 MOE / cEt spacer, or 2-1-10-2-1 MOE / cEt spacer.

11. The compound or a salt thereof according to any one of claims 4 to 10, wherein the oligonucleotide has any of the oligonucleotide modifications shown in Table 1, Table 2 or Table 3.

12. The compound or a salt thereof according to any one of claims 1 to 11, wherein, The oligonucleotide comprises a continuous nucleotide sequence with modifications shown in one or more of SEQ ID NO:1-27, SEQ ID NO:30-48, SEQ ID NO:50-77, SEQ ID NO:80-94, SEQ ID NO:102-112, SEQ ID NO:114-137 and SEQ ID NO:180-200; Optionally, the oligonucleotide comprises a continuous nucleotide sequence with modifications selected from one or more of the following: SEQ ID NO:57-63, SEQ ID NO:73-77, SEQ ID NO:80-94, SEQ ID NO:102-110, SEQ ID NO:114-137, and SEQ ID NO:180-200; or Optionally, the oligonucleotide comprises one or more of the consecutive nucleotides shown in SEQ ID NO: 57, 59, 61, 62, 63, 73, 74, 75, 77, 80, 86, 88, 90, 92, 93, 94, 102, 108, 109, 114, 115, 130, 132, 133, 134, 136, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 200.

13. The compound or a salt thereof according to any one of claims 3 to 12, wherein the compound comprises a targeting ligand conjugated to an oligonucleotide.

14. The compound of claim 13 or a salt thereof, wherein the targeting ligand is selected from L96, THAGN3, 59GN3, LICA-1, LICA-2, LICA-3, (NAG25), (NAG25)s, (NAG37) or (NAG37)s; preferably, the targeting ligand is THAGN3 or 59GN3; more preferably, the targeting ligand is 59GN3.

15. The compound or a salt thereof according to claim 13 or 14, wherein the targeting ligand is conjugated to the 5' end or 3' end of the oligonucleotide; preferably conjugated to the 5' end of the oligonucleotide; more preferably the targeting ligand is attached to the oxygen atom at the 5' position of the 5' end nucleotide of the oligonucleotide.

16. The compound of claim 15 or a salt thereof, wherein the compound is selected from any of the compounds shown in SEQ ID NO: 180 to 200.

17. A composition comprising the compound of any one of claims 1 to 16 or a salt thereof, and a pharmaceutically acceptable carrier.

18. Use of the compound of any one of claims 1-16 or a salt thereof, or the composition of claim 17, in the preparation of a medicament for the prevention, treatment, or relief of a disease or symptom, said disease or symptom being a PKK-related disease or symptom; or Use of the compound of any one of claims 1-16 or a salt thereof or the composition of claim 17 in a medicament for the prevention, treatment or relief of a disease or symptom, wherein the disease or symptom is a PKK-related disease or symptom; or A method for preventing, treating, or alleviating a disease or symptom, comprising administering to a subject a compound or salt thereof as claimed in any one of claims 1-16 or a composition as claimed in claim 17, wherein the disease or symptom is a PKK-related disease or symptom; Optional, PKK-related diseases or symptoms include edema, swelling, thrombosis, embolism or infarction; Optionally, the edema is ocular edema, macular edema, cerebral edema, angioedema, or hereditary angioedema (HAE); the thrombosis is deep vein thrombosis; the embolism is pulmonary embolism; and the infarction is myocardial infarction or stroke.